liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Safety and efficacy of the combination of pegylated interferon-alpha 2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients
St Olavs Hospital, Norway; Norwegian University of Science and Technology NTNU, Norway.
Aarhus University Hospital, Denmark.
Skåne University Hospital, Sweden.
University of Helsinki, Finland; Helsinki University Hospital, Sweden.
Visa övriga samt affilieringar
2016 (Engelska)Ingår i: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 30, nr 9, s. 1853-1860Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Dasatinib (DAS) and interferon-a have antileukemic and immunostimulatory effects and induce deep responses in chronic myeloid leukemia (CML). We assigned 40 newly diagnosed chronic-phase CML patients to receive DAS 100 mg o.d. followed by addition of pegylated interferon-alpha 2b (PegIFN) after 3 months (M3). The starting dose of PegIFN was 15 mu g/week and it increased to 25 mu g/week at M6 until M15. The combination was well tolerated with manageable toxicity. Of the patients, 84% remained on PegIFN at M12 and 91% (DAS) and 73% (PegIFN) of assigned dose was given. Only one patient had a pleural effusion during first year, and three more during the second year. After introduction of PegIFN we observed a steep increase in response rates. Major molecular response was achieved in 10%, 57%, 84% and 89% of patients at M3, M6, M12 and M18, respectively. At M12, MR4 was achieved by 46% and MR4.5 by 27% of patients. No patients progressed to advanced phase. In conclusion, the combination treatment appeared safe with very promising efficacy. A randomized comparison of DAS +/- PegIFN is warranted.

Ort, förlag, år, upplaga, sidor
NATURE PUBLISHING GROUP , 2016. Vol. 30, nr 9, s. 1853-1860
Nationell ämneskategori
Hematologi
Identifikatorer
URN: urn:nbn:se:liu:diva-132071DOI: 10.1038/leu.2016.121ISI: 000383786400003PubMedID: 27133821OAI: oai:DiVA.org:liu-132071DiVA, id: diva2:1038424
Anmärkning

Funding Agencies|Bristol-Myers Squibb; Norwegian University of Science and Technology (NTNU, Trondheim, Norway)

Tillgänglig från: 2016-10-18 Skapad: 2016-10-17 Senast uppdaterad: 2017-11-29

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Sök vidare i DiVA

Av författaren/redaktören
Dreimane, Arta
Av organisationen
Institutionen för klinisk och experimentell medicinHälsouniversitetetHematologiska kliniken US
I samma tidskrift
Leukemia
Hematologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 80 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf